Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD)
Standard
Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD) : defining novel phenotypes through hierarchical cluster analysis. / Guenther, Ulf-Peter; Varon, Raymonda; Schlicke, Maria; Dutrannoy, Véronique; Volk, Alexander; Hübner, Christoph; von Au, Katja; Schuelke, Markus.
In: HUM MUTAT, Vol. 28, No. 8, 08.2007, p. 808-15.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD)
T2 - defining novel phenotypes through hierarchical cluster analysis
AU - Guenther, Ulf-Peter
AU - Varon, Raymonda
AU - Schlicke, Maria
AU - Dutrannoy, Véronique
AU - Volk, Alexander
AU - Hübner, Christoph
AU - von Au, Katja
AU - Schuelke, Markus
N1 - (c) 2007 Wiley-Liss, Inc.
PY - 2007/8
Y1 - 2007/8
N2 - Autosomal recessive spinal muscular atrophy with respiratory distress (SMARD) is a heterogeneous disorder. Mutations in the immunoglobulin micro-binding protein gene (IGHMBP2) lead to SMARD1, but clinical criteria that delineate SMARD1 from other SMARD syndromes are not well established. Here we present a retrospective clinical and genetic study to determine the criteria that would predict the presence or absence of IGHMBP2 mutations. From 141 patients with respiratory distress and a spinal muscular atrophy phenotype we recorded the clinical features through a questionnaire and sequenced the entire coding region of IGHMBP2. In 47 (33%) patients we identified IGHMBP2 mutations, 14 of which were not described before. Clinical features and combinations thereof associated with the presence of IGHMBP2 mutations were discovered through hierarchical cluster analysis. This method detects common traits not evident at first sight by grouping items according to their similarity. The combination of "manifestation of respiratory failure between 6 weeks and 6 months" AND ("presence of diaphragmatic eventration" OR "preterm birth") predicted the presence of IGHMBP2 mutations with 98% sensitivity and 92% specificity. Non-SMARD1 patients fell into two different symptom clusters, mainly separated by the age at respiratory failure and the presence of multiple congenital contractures. The 14 novel IGHMBP2 mutations comprised missense, frameshift, splice-site, and nonsense mutations. All missense mutations altered conserved residues within or adjacent to the putative DNA helicase domain. The c.1235+3A>G splice-site mutation did not entirely suppress correct splicing and we found a residual wild-type IGHMBP2 mRNA steady-state level of 24.4+/-6.9%, which was, however, not sufficient to avert SMARD1 in this patient.
AB - Autosomal recessive spinal muscular atrophy with respiratory distress (SMARD) is a heterogeneous disorder. Mutations in the immunoglobulin micro-binding protein gene (IGHMBP2) lead to SMARD1, but clinical criteria that delineate SMARD1 from other SMARD syndromes are not well established. Here we present a retrospective clinical and genetic study to determine the criteria that would predict the presence or absence of IGHMBP2 mutations. From 141 patients with respiratory distress and a spinal muscular atrophy phenotype we recorded the clinical features through a questionnaire and sequenced the entire coding region of IGHMBP2. In 47 (33%) patients we identified IGHMBP2 mutations, 14 of which were not described before. Clinical features and combinations thereof associated with the presence of IGHMBP2 mutations were discovered through hierarchical cluster analysis. This method detects common traits not evident at first sight by grouping items according to their similarity. The combination of "manifestation of respiratory failure between 6 weeks and 6 months" AND ("presence of diaphragmatic eventration" OR "preterm birth") predicted the presence of IGHMBP2 mutations with 98% sensitivity and 92% specificity. Non-SMARD1 patients fell into two different symptom clusters, mainly separated by the age at respiratory failure and the presence of multiple congenital contractures. The 14 novel IGHMBP2 mutations comprised missense, frameshift, splice-site, and nonsense mutations. All missense mutations altered conserved residues within or adjacent to the putative DNA helicase domain. The c.1235+3A>G splice-site mutation did not entirely suppress correct splicing and we found a residual wild-type IGHMBP2 mRNA steady-state level of 24.4+/-6.9%, which was, however, not sufficient to avert SMARD1 in this patient.
KW - Chi-Square Distribution
KW - Cluster Analysis
KW - Cohort Studies
KW - DNA Mutational Analysis
KW - DNA, Complementary
KW - DNA-Binding Proteins
KW - Gene Expression Regulation
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Muscular Atrophy, Spinal
KW - Mutation
KW - Phenotype
KW - Respiration Disorders
KW - Transcription Factors
U2 - 10.1002/humu.20525
DO - 10.1002/humu.20525
M3 - SCORING: Journal article
C2 - 17431882
VL - 28
SP - 808
EP - 815
JO - HUM MUTAT
JF - HUM MUTAT
SN - 1059-7794
IS - 8
ER -